Objectives: COVID-19 vaccine was rolled out for the public in August 2021 in Zamfara state, Northen Nigeria. We determined the factors influencing COVID-19 vaccine acceptance.
Settings: We executed a community-based analytical cross-sectional study during the first 4 months of the second phase of the COVID-19 (Oxford/AstraZeneca) mass vaccination campaign in Zamfara state.
Background: Mechanical thrombectomy (MT) is the standard of care for eligible acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) since 2015.
Aim: Our aim was to determine the key challenges for MT implementation and access worldwide.
Methods: We conducted an international online survey consisting of 37 questions, distributed through the World Stroke Organization network, and as invited by co-authors between December 2022 and March 2023.
Background: The Federal Retail Pharmacy Program (FRPP) integrated pharmacies as partners in the national effort to maximize vaccination during the COVID-19 public health emergency.
Objective: The objective of this study was to quantify the contribution of pharmacies participating in FRPP to COVID-19 vaccination efforts during December 2020-September 2023 across sociodemographic groups in the United States.
Methods: Data on COVID-19 vaccine doses administered reported to Centers for Disease Control and Prevention by FRPP and jurisdictional immunization information systems of all 50 states, the District of Columbia, and U.
Introduction: Globally, hypertension is considered a public health problem affecting over 1.3 billion individuals of which 60% need reminders to take medication to achieve adherence, optimal blood pressure and avert complications. Literature shows electronic short message reminders (eSMS) improved medication adherence.
View Article and Find Full Text PDFThe Federal Retail Pharmacy Program (FRPP) facilitated integration of pharmacies as partners in national efforts to scale up vaccination capacity during the COVID-19 pandemic emergency response. To evaluate FRPP's contribution to vaccination efforts across various sociodemographic groups, data on COVID-19 bivalent mRNA vaccine doses administered during September 1, 2022-September 30, 2023, were evaluated from two sources: 1) FRPP data reported directly to CDC and 2) jurisdictional immunization information systems data reported to CDC from all 50 states, the District of Columbia, U.S.
View Article and Find Full Text PDF